Given that drugs placed in Schedule I of the Controlled Substances Act (CSA) are deemed (among other things) to have “no accepted medical use”, one might think that an FDA approval of a medicine containing such a drug—the de facto recognition that a drug has an accepted medical use in the U.S.—might necessitate its rescheduling. It is true that once approved by the FDA, the DEA generally has up to…
